New Antibiotics to Combat the Threat of Resistant Bacterial Infections
- Melinta Therapeutics is dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development of novel antibiotics that provide new and better therapeutic solutions.
- In June 2017, Melinta received U.S. Food and Drug Administration (“FDA”) approval for its novel antibiotic, Baxdela, for acute bacterial skin and skin structure infections (ABSSSI) and is pursuing development for other potential indications.
- Through the application of Nobel Prize-winning science, Melinta is also committed to developing a new class of antibiotics designed to overcome the multi- and extremely-drug-resistant pathogens for which there are few to no options. These “superbugs,” known collectively as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli), cause the majority of life-threatening hospital infections.
- Combating the threat of bacterial infections by discovering, developing and commercializing novel antibiotics.
- In the U.S., at least two million people acquire serious bacterial infections that are resistant to one or more antibiotics each year. Antibiotic-resistant infections also add considerable and potentially avoidable costs to the U.S. healthcare system. According to the U.S. Centers for Disease Control and Prevention’s Antibiotic Resistance Threat Report, the total estimated financial cost of antibiotic resistance to the U.S. may reach as high as $20 billion in excess direct healthcare costs, with additional societal costs for lost productivity as high as $35 billion a year.
“Vatera is not only an investor but also a trusted partner for Melinta. The team’s deep biopharma expertise, broad set of industry relationships and valuable strategic insights are supporting our mission of bringing novel antibiotics to market.”
Eugene Sun, MD
Chief Executive Officer